scroll to top
0

EBSCO Auth Banner

Let's find your institution. Click here.

Advanced Search Results For "AROMATASE inhibitors"

1 - 10 of 11,238 results for
 "AROMATASE inhibitors"
Results per page:

Chemicals of environmental concern as inhibitors of human placental 3β-hydroxysteroid dehydrogenase 1 and aromatase: Screening and docking analysis.

Publication Type: Academic Journal

Source(s): Chemico-biological interactions [Chem Biol Interact] 2022 Dec 01; Vol. 368, pp. 110243. Date of Electronic Publication: 2022 Oct 28.

Authors:

Abstract: Many environmental pollutants act as endocrine-disrupting compounds by inhibiting human placental 3β-hydroxysteroid dehydrogenase/Δ 5-4 isomerase type 1 (HSD3B1) and aromatase (CYP19A1) activities. In this study, we screened 13 chemicals of environment...

View details

Medicinal chemistry aspects and synthetic strategies of coumarin as aromatase inhibitors: an overview.

Publication Type: Academic Journal

Source(s): Medical oncology (Northwood, London, England) [Med Oncol] 2022 Dec 05; Vol. 40 (1), pp. 41. Date of Electronic Publication: 2022 Dec 05.

Abstract: Coumarin is a bicyclic oxygen bearing heterocyclic scaffold formed by fusion of benzene with the pyrone ring. Because of its unique physicochemical characteristics and the ease with which it may be transformed into a wide range of functionalized coumar...

View details

The effect of aromatase inhibitors against possible testis toxicity in pembrolizumab treated rats.

Publication Type: Academic Journal

Source(s): Andrologia [Andrologia] 2022 Nov; Vol. 54 (10), pp. e14557. Date of Electronic Publication: 2022 Aug 14.

Abstract: Pembrolizumab is a monoclonal antibody. Anastrozole is an infertility inhibitor of aromatase. Resveratrol is an antioxidant polyphenol in the reproductive system. This study was planned to demonstrate the protective effects of anastrozole and resveratr...

View details

4th generation nonsteroidal aromatase inhibitors: An iterative SAR-guided design, synthesis, and biological evaluation towards picomolar dual binding inhibitors.

Publication Type: Academic Journal

Source(s): European journal of medicinal chemistry [Eur J Med Chem] 2022 Oct 05; Vol. 240, pp. 114569. Date of Electronic Publication: 2022 Jul 06.

Abstract: One in every eight women will be diagnosed with breast cancer during their lifetime and approximately 70% of all patients are oestrogen receptor (ER) positive depending upon oestrogen for their growth accounting for third generation aromatase (CYP19A1)...

View details

Gene Expression Profiling between Patient Groups with High and Low Ki67 Levels after Short-term Preoperative Aromatase Inhibitor Treatment for Breast Cancer.

Publication Type: Academic Journal

Source(s): Acta medica Okayama [Acta Med Okayama] 2022 Aug; Vol. 76 (4), pp. 399-408.

Abstract: According to a recent report, a low Ki67 level after short-term preoperative hormone therapy (post-Ki67) might suggest a more favorable prognosis compared with a high post-Ki67 level in patients with hormone receptorpositive/human epidermal growth fact...

View details

Single-digit nanomolar inhibitors lock the aromatase active site via a dualsteric targeting strategy.

Publication Type: Academic Journal

Source(s): European journal of medicinal chemistry [Eur J Med Chem] 2022 Dec 15; Vol. 244, pp. 114802. Date of Electronic Publication: 2022 Sep 30.

Abstract: The most frequently diagnosed breast cancer (BC) type in women expresses estrogen receptor (ER) and depends on estrogens for its growth, being classified as ER positive (ER+). The gold standard therapy for the treatment of this tumor relies on the inhi...

View details

Management of Growth Disorders in Puberty: GH, GnRHa, and Aromatase Inhibitors: A Clinical Review.

Publication Type: Academic Journal

Source(s): Endocrine reviews [Endocr Rev] 2023 Jan 12; Vol. 44 (1), pp. 1-13.

Abstract: Pubertal children with significant growth retardation represent a considerable therapeutic challenge. In growth hormone (GH) deficiency, and in those without identifiable pathologies (idiopathic short stature), the impact of using GH is significantly h...

View details

Use of aromatase inhibitors in menopausal deep endometriosis: a case report and literature review.

Publication Type: Academic Journal

Source(s): Climacteric : the journal of the International Menopause Society [Climacteric] 2022 Jun; Vol. 25 (3), pp. 235-239. Date of Electronic Publication: 2021 Oct 25.

Abstract: We report and review the clinical effectiveness of aromatase inhibitors in a patient with refractory, recurrent and infiltrating endometriosis. We demonstrate excellent clinical, radiological and endoscopic responses after failure of multiple other mod...

View details

Interaction of letrozole and its degradation products with aromatase: chemometric assessment of kinetics and structure-based binding validation.

Publication Type: Academic Journal

Source(s): Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2022 Dec; Vol. 37 (1), pp. 1600-1609.

Abstract: Letrozole is one of the most prescribed drugs for the treatment of breast cancer in post-menopausal women, and it is endowed with selective peripheral aromatase inhibitory activity. The efficacy of this drug is also a consequence of its long-lasting ac...

View details

Comparison of the clinical effectiveness of treatments for aromatase inhibitor-induced arthralgia in breast cancer patients: A systematic review with network meta-analysis.

Publication Type: Academic Journal

Source(s): Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2023 Jan; Vol. 181, pp. 103898. Date of Electronic Publication: 2022 Dec 16.

Abstract: Aromatase inhibitor-induced arthralgia (AIA) contributes to poor adherence of aromatase inhibitor therapies in patients with breast cancer. A systematic review using network meta-analysis (NMA) was conducted to examine the clinical effectiveness of mul...

View details
sponsored